MD
MDNAF.US Medicenna Therapeutics Corp
- Market cap
- USD 23.5M
- P/E
- -
- P/B
- 21.38x
- ROE
- -1,215.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is MDNAF.US undervalued?
Graham numberThe Graham number of Medicenna Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medicenna Therapeutics Corp fundamental analysis
No fundamental analysis for Medicenna Therapeutics Corp yet.
Medicenna Therapeutics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113,…
Full company profileMedicenna Therapeutics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medicenna Therapeutics Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
| Operating Income | -7.70M | -7.42M | -4.73M | -8.24M | -17.4M | -22.5M | -16.3M | -18.7M | -20.4M | -22.4M | -21.8M |
| EBITDA | - | - | - | - | - | - | -16.3M | -18.7M | -20.4M | -22.3M | -21.7M |
| Net Income | -7.63M | -7.47M | -4.71M | -8.28M | -17.3M | -22.6M | -10.0M | -25.5M | -11.8M | -18.4M | -20.3M |
| EPS | - | - | - | -0.18 | -0.32 | -0.41 | -0.14 | -0.37 | -0.15 | -0.22 | -0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 14.5M | 4.37M | 5.19M | 38.0M | 42.3M | 23.5M | 36.4M | 19.1M | 28.4M | 8.45M | 8.25M |
| Total Liabilities | 7.83M | 2.21M | 2.57M | 1.85M | 4.11M | 2.62M | 6.96M | 13.9M | 9.29M | 5.97M | 6.58M |
| Shareholders' Equity | 6.66M | 2.16M | 2.62M | 36.1M | 38.1M | 20.8M | 29.5M | 5.19M | 19.1M | 2.48M | 1.67M |
| Cash & Short-term Investments | 14.0M | 3.94M | 2.37M | 22.7M | 30.4M | 20.5M | 33.6M | 17.0M | 24.8M | 6.25M | 5.69M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.31M | -10.1M | -8.04M | -8.95M | -15.3M | -23.6M | -12.7M | -16.3M | -16.5M | -17.9M | -17.7M |
| Capital Expenditure | 5.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.0K | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | -5.42M | -15.3M | -23.6M | -12.7M | -16.3M | -16.5M | -17.9M | -17.7M |
| Ratios | |||||||||||
| ROE | -114.6% | -345.3% | -179.9% | -22.9% | -45.3% | -108.4% | -34.1% | -490.6% | -61.8% | -741.7% | -1,215.1% |
| ROA | -52.7% | -170.7% | -90.8% | -21.8% | -40.9% | -96.3% | -27.6% | -133.1% | -41.6% | -217.8% | -246.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Medicenna Therapeutics Corp dividends
Medicenna Therapeutics Corp has not paid dividends in the last 9 fiscal years.
Who owns Medicenna Therapeutics Corp
- Insiders 18.82%
- Institutions 0.00%
- Public & others 81.18%
- Shares outstanding 92.3M
- Free float 74.3M
Medicenna Therapeutics Corp company profile
- Company name
- Medicenna Therapeutics Corp
- Ticker
- MDNAF.US
- Exchange
- USA Stocks
- Listed since
- Aug 27, 2001
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- March
- Address
- 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2
- Phone
- 416-964-5442
- Website
- medicenna.com
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Medicenna Therapeutics Corp management
5- Dr. Fahar Merchant Ph.D.Founder, Chairman, President & CEO · born 1957
- Ms. Rosemina Merchant B.Sc., M.E.ScFounder & Chief Development Officer · born 1957
- Mr. David Hyman CA, CBVChief Financial Officer · born 1973
- Dr. Nageatte Ibrahim M.D.Chief Medical Officer
- Dr. Samuel R. Denmeade M.D.Scientific Advisor